Northeast Pharmaceutical Group Co., Ltd. specializes in the production and marketing of pharmaceutical ingredients and preparations. The group's products include antibiotics, vitamins, cardiovascular treatments, anesthetics, medical plants, etc. China accounts for 86.3% of net sales.

Employees

5,727

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
06/26/06	CN¥4.580	+1.55%	1,31,76,290
03/26/03	CN¥4.510	+1.35%	1,10,43,843
02/26/02	CN¥4.450	+1.60%	1,13,34,311
01/26/01	CN¥4.380	+3.30%	1,16,88,960
30/26/30	CN¥4.240	-3.64%	1,11,40,481

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 06/07/2026			5-day change	1st Jan Change
4.580 ^CNY	+1.55%		+9.05%	-12.26%

16/06	Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2025, Payable on 23 June 2026	CI
27/04	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	653.61Cr 96Cr 84Cr 77Cr 72Cr 136.77Cr 9.17TCr 138.84Cr 928.73Cr 361.04Cr 4.51TCr 361.44Cr 353.68Cr 16TCr	P/E 2024	18.2x	P/E 2025	29x
Enterprise Value	504.55Cr 74Cr 65Cr 60Cr 56Cr 105.58Cr 7.08TCr 107.18Cr 716.94Cr 278.71Cr 3.48TCr 279.02Cr 273.03Cr 12TCr	EV / Sales 2024	0.62x	EV / Sales 2025	0.84x
Free-Float	39.51%	Yield 2024	1.9%	Yield 2025	1.05%

16/06	Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2025, Payable on 23 June 2026	CI
27/04	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03/04	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/04	Northeast Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 23, 2026	CI
28/25/28	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
09/25/09	Northeast Pharmaceutical Unit Gets Clinical Trial Approval for Glioma Treatment	MT
08/25/08	Northeast Pharmaceutical Appoints CFO	MT
02/25/02	Northeast Pharmaceutical CFO Resigns	MT
26/25/26	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
05/25/05	Northeast Pharmaceutical Gets Nod to Market Antiobiotic in Europe	MT
28/25/28	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
26/25/26	Northeast Pharmaceutical Group Co., Ltd. Announces Directorate Appointments	CI
26/25/26	Northeast Pharmaceutical Group Co., Ltd. Approves Cash Dividend on (A Shares) for 2024, Payable on 23 June 2025	CI

1 day	+1.55%
1 week	+9.05%
Current month	+8.02%
1 month	+3.15%
3 months	-13.91%
6 months	-13.58%
Current year	-12.26%

Northeast Pharmaceutical Group Co., Ltd. Share Price

Stocks

000597

CNE0000009G0

Pharmaceuticals

Valuation: Northeast Pharmaceutical Group Co., Ltd.

Chart: Northeast Pharmaceutical Group Co., Ltd.

Latest news : Northeast Pharmaceutical Group Co., Ltd.

Press Releases: Northeast Pharmaceutical Group Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Northeast Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	4.17	4.61
1 month	4.09	4.73
Current year	4.09	5.73
1 year	4.09	6.68
3 years	3.72	6.69
5 years	3.72	9.3
10 years	3.72	9.3

Manager	Title	Age	Since
Yong Gang Cai CEO	Chief Executive Officer	46	21/01/2025
Xin Li DFI	Director of Finance/CFO	46	06/09/2025
Dong Sheng Yan IRC	Investor Relations Contact	42	01/07/2024

Director	Title	Age	Since
Kai Zhou CHM	Chairman	62	21/01/2025
Xin Hua Ao BRD	Director/Board Member	62	18/07/2018
Cheng Ren Huang BRD	Director/Board Member	62	18/07/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/22/01	Zhengwei	Buy		36,000	0.0027%
26/22/26	Yan Liu	Buy	Executive/Senior Manager	100	0.0000%
25/22/25	Zhengwei	Buy		28,100	0.0021%

	2024	2025
Net sales	750.26Cr 110.53Cr 97Cr 89Cr 83Cr 156.99Cr 11TCr 159.38Cr 1.07TCr 414.43Cr 5.17TCr 414.89Cr 405.98Cr 18TCr	707.49Cr 104.23Cr 91Cr 84Cr 78Cr 148.04Cr 9.92TCr 150.29Cr 1.01TCr 390.8Cr 4.88TCr 391.24Cr 382.84Cr 17TCr
Net income	41Cr 6.04Cr 5.28Cr 4.85Cr 4.52Cr 8.58Cr 574.91Cr 8.71Cr 58Cr 23Cr 282.6Cr 23Cr 22Cr 973.82Cr	26Cr 3.83Cr 3.35Cr 3.08Cr 2.87Cr 5.44Cr 364.81Cr 5.52Cr 37Cr 14Cr 179.32Cr 14Cr 14Cr 617.94Cr
Net Debt	-287.58Cr -42Cr -37Cr -34Cr -32Cr -60Cr -4.03TCr -61Cr -408.63Cr -158.85Cr -1.98TCr -159.03Cr -155.62Cr -6.83TCr	-149.05Cr -22Cr -19Cr -18Cr -16Cr -31Cr -2.09TCr -32Cr -211.79Cr -82Cr -1.03TCr -82Cr -81Cr -3.54TCr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHEAST PHARMACEUTICAL GROUP CO., LTD.	+1.55%	+9.05%	-14.23%	-11.75%	95Cr
ELI LILLY AND COMPANY	-1.50%	-2.69%	+54.86%	+158.38%	1,08200Cr
JOHNSON & JOHNSON	-2.24%	-0.36%	+65.90%	+59.40%	63TCr
ABBVIE INC.	-2.18%	+0.39%	+36.07%	+86.02%	46TCr
ROCHE HOLDING AG	-2.79%	+1.37%	+31.00%	+23.05%	34TCr
ASTRAZENECA PLC	-2.46%	-1.38%	+37.99%	+36.52%	30TCr
NOVARTIS AG	-2.20%	-0.87%	+28.16%	+42.69%	29TCr
NOVO NORDISK A/S	-1.77%	+1.97%	-27.22%	-40.66%	22TCr
AMGEN INC.	-2.69%	+0.85%	+24.13%	+63.08%	20TCr
GILEAD SCIENCES, INC.	-1.66%	+2.05%	+15.33%	+69.10%	16TCr
Average	-1.85%	+4.81%	+25.20%	+48.58%	36.93TCr
Weighted average by Cap.	-2.09%	+5.43%	+40.38%	+79.84%